Aminoglycoside prescribing and surveillance in cystic fibrosis.
Tan
Kelvin H-V
KH
Division of Respiratory Medicine, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. Kelvin.Tan@nottingham.ac.uk
Mulheran
Michael
M
Knox
Alan J
AJ
Smyth
Alan R
AR
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications* / Q000378:metabolism; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods / Q000592:standards* / Q000706:statistics & numerical data; D011307:Drug Prescriptions / Q000592:standards* / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000592:standards / Q000706:statistics & numerical data*; D006311:Hearing Disorders / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D007677:Kidney Function Tests; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000706:statistics & numerical data; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents